Search

Displaying results 2171 - 2180 of 10000 in total
  1. Drug

    Aurothioglucose

    go.drugbank.com/drugs/DB09121
    ApprovedWithdrawn

    Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis [A32326].

  2. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    [A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833] … [L10833] This medication was first marketed in Russia and India before being granted FDA approval.

  3. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults. … It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells.

  4. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.

  5. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019. … [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug

  6. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.

  7. Drug

    Alfacalcidol

    go.drugbank.com/drugs/DB01436
    ApprovedInvestigationalNutraceutical

    [A234044] It plays an essential function in calcium homeostasis and bone metabolism. … Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones.

  8. Drug

    Asparagine

    go.drugbank.com/drugs/DB00174
    ApprovedNutraceuticalWithdrawn

    (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed) … A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase.

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSION
  9. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

  10. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    Sertaconazole nitrate is an antifungal medication of the imidazole class. It is available in topical formulations for the treatment of skin infections such as athlete's foot.